Launch of Novacyt’s first fully lyophilised PROmate® assays
04 Agosto 2022 - 3:00AM
Business Wire
New freeze-dried, direct-to-PCR assays
extend the global reach of Novacyt’s PCR portfolio with ability to
be transported at ambient temperatures
Two PROmate® lyophilised assays initially
launched for COVID-19, with a broader portfolio of lyophilised
direct-to-PCR assays in development
Regulatory News:
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) ("Novacyt", the
"Company" or the "Group"), an international specialist in clinical
diagnostics, announces the launch of the Company’s first fully
lyophilised (freeze-dried), direct-to-PCR assays. This new class of
PROmate® assay enables shipping and transportation at ambient
temperatures to remote regions or in areas without a centralised
cold storage supply chain, providing an extended global reach for
Novacyt’s PCR portfolio.
The first two lyophilised, direct-to-PCR assays to be launched
are PROmate® COVID-19 (q32) 2G Dry and PROmate® COVID-19 (q16) 2G
Lite Dry, further expanding Novacyt’s COVID-19 detection portfolio
and meeting customer distribution requirements for assays which can
be deployed more easily in remote or developing regions.
These new assays complement Novacyt’s COVID-19 variant detection
portfolio, with a broader portfolio of lyophilised direct-to-PCR
assays in development for the detection of other infectious
diseases.
Both PROmate® COVID-19 (q32) 2G Dry and PROmate® COVID-19 (q16)
2G Lite Dry are based on the PROmate® COVID-19 direct-to-PCR
chemistry, and target the ORF1ab gene and the nsp16 gene, a
non-structural protein of SARS-CoV-2. They are designed to function
as a total workflow solution PCR amplification and analysis, with
PROmate® COVID-19 (q32) 2G Dry configured for use on the Company’s
q32 instrument, and PROmate® COVID-19 (q16) 2G Lite Dry configured
for use on the Company’s q16 instrument.
David Allmond, Chief Executive Officer of Novacyt,
commented: “Developing these lyophilised, or freeze-dried,
direct-to-PCR assays was highlighted as a key target in the
strategy set out at our full year results and therefore are an
indication of our continued delivery in this regard. Through the
development of our portfolio, and the delivery of this new assay
type, we are able to ensure that more of Novacyt’s products are
available across an even broader geographic area, and that we
remain at the forefront in our ability to act as a global first
responder. We continue to monitor customer need and use our
bioinformatics surveillance capabilities as we look to add further
lyophilised PROmate® assays to our portfolio.”
For further information, please refer to
www.novacyt.com.
About Novacyt Group The Novacyt Group is an international
diagnostics business generating an increasing portfolio of in vitro
and molecular diagnostic tests. Its core strengths lie in
diagnostics product development, commercialisation, contract design
and manufacturing. The Company supplies an extensive range of
high-quality assays and reagents worldwide. The Group directly
serves microbiology, haematology and serology markets as do its
global partners, which include major corporates.
For more information, please refer to the website:
www.novacyt.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220803006040/en/
Novacyt SA David Allmond, Chief Executive Officer James
McCarthy, Chief Financial Officer +44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470
0470
Numis Securities Limited (Joint Broker) Freddie Barnfield
/ James Black +44 (0)20 7260 1000
Allegra Finance (French Listing Sponsor) Rémi Durgetto /
Yannick Petit +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /
y.petit@allegrafinance.com
FTI Consulting (International) Victoria Foster Mitchell /
Alex Shaw +44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
Alex.Shaw@fticonsulting.com / Novacyt.group@fticonsulting.com
FTI Consulting (France) Arnaud de Cheffontaines +33
(0)147 03 69 48 arnaud.decheffontaines@fticonsulting.com
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novacyt (EU:ALNOV)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024